

**A STEPWISE IN VIVO STUDY TO DETERMINE THE SUN PROTECTION
FACTOR OF FOUR PRODUCTS FOLLOWING FDA STATIC TEST
METHOD.**

Prepared for:

Supergoop
200 E Grayson, Suite 112,
San Antonio,
TX, 78215,
USA

Prepared by:

[REDACTED]

[REDACTED]

Final Report: 5th August 2022

**A STEPWISE IN VIVO STUDY TO DETERMINE THE SUN PROTECTION
FACTOR OF FOUR PRODUCTS FOLLOWING FDA STATIC TEST METHOD.**

I declare that the following report constitutes a true and faithful account of the procedures adopted and the results obtained in the performance of this study. The aspects of the study conducted by [REDACTED] were performed, where relevant, in accordance with the principles of Good Clinical Research Practice.

QUALITY ASSURANCE STATEMENT

This report has been audited and is considered to be an accurate description of the methods used and an accurate presentation of the data obtained during the conduct of the study.

CONTENTS

INTRODUCTION AND OBJECTIVE	7
MATERIALS AND METHODS	7
1. study design	7
2. selection of subjects	7
2.1. Screening	7
2.2. Inclusion Criteria	7
2.3. Exclusion Criteria	7
2.4. Prohibitions and Restrictions	8
3. Materials	8
3.1. Test Articles.....	8
4. Method	9
4.1. ARTIFICIAL LIGHT SOURCE	9
4.2. AMBIENT CONDITIONS	10
4.3. INFORMED CONSENT, SCREENING AND TEST SITE IDENTIFICATION.....	10
4.4. TREATMENT.....	10
4.4.1 MED (MINIMAL ERYTHEMAL DOSE) DETERMINATION	10
4.4.2 MED ASSESSMENT	10
4.4.3 TEST ARTICLE SPF (STATIC) DETERMINATION.....	10
4.4.4 SPF DETERMINATION	11
4.4.5 SPF ASSESSMENT AND CALCULATION	11
4.5. SKIN ASSESSMENT	12
5. study ethics	13
5.1 DECLARATION OF HELSINKI.....	13
5.2 INDEMNITY PROVISION	13
6. quality assurance	13
7. retention of data	13
8. references	14
RESULTS	15
1 LOCATION AND DATES OF THE STUDY	15
2 SUBJECTS	15
3 ADVERSE EVENTS, ADVERSE REACTIONS AND SUBJECTS NOT COMPLETING THE STUDY	15
4 QUALITY OF UV IRRADIATION	15
5 ASSESSMENTS	15

SUMMARY

1. This was a stepwise, single-blind study in healthy volunteers to determine the sun protection factor (SPF) of four sun protection products when compared to unprotected skin after the sites were exposed to an artificial "sun" light source based on the FDA Sunscreen Final Rule; 21 CFR Parts 201 and 310 for the determination of the SPF value.
2. Each subject was treated with a series of five light exposures in order to determine the MED for unprotected skin. Subsites were graded 20 ± 4 (16 to 24) hours after the MED exposure. The MED was assessed as being the lowest dose that elicited minimally perceptible erythema at a subsite.
3. Following MED determination, six test areas were outlined on the back, above the MED test area. The control standard preparation (mean SPF 16.3) was applied to one area, one area remained untreated to re-determine the MED and the test preparations were applied to the four remaining areas. UV exposures commenced 15 – 30 minutes after application of the test products. Length of exposure was determined by reference to the individual subject's MED. For products with an expected SPF greater than 15, the exposures will be MEDu times 0.76x, 0.87x, 1.00x, 1.15x and 1.32x (where x equals the expected SPF of the product).
4. The erythema level of the test and control subsites was assessed 20 ± 4 (16 to 24) hours after exposure and the MED for "protected" skin was determined. Individual and mean SPF values were then calculated.
5. The static SPF value for the standard preparation was 16.33 (Label SPF = 15). The study can therefore be considered valid.
6. Mean Static SPF results (N=10) for the test articles:

Test article 1 – Lipshade 100% Mineral SPF 30 (Shade #4) [REDACTED] achieved a mean SPF value of 33.15. The calculated Label SPF = 31.

Test article 2 – Lipshade 100% Mineral SPF 30 (Shade #3) [REDACTED] achieved a mean SPF value of 33.60. The calculated Label SPF = 32.

Test article 3 – Lipshade 100% Mineral SPF 30 (Shade #2) [REDACTED] Expected SPF30) achieved a mean SPF value of 33.15. The calculated Label SPF = 31.

Test article 4 – Lipshade 100% Mineral SPF 30 (Shade #1) [REDACTED] achieved a mean SPF value of 33.15. The calculated Label SPF = 31.

KEY STUDY PERSONNEL AND RESPONSIBILITIES

General Responsibilities

The Principal Investigator (PI) is responsible for ensuring sufficient resources are available to conduct the study and is responsible for the study design, review of the study protocol and report, and ensuring that they concur with the study findings report.

The Project Supervisor (PS) will be responsible for the conduct of the study on a daily basis.

The Project Manager (PM) will be involved with the study design, compilation of study results, and writing the study protocol and report.

The Project Coordinator (PC) will be the primary point of contact on behalf of the Sponsor of this study and will represent the Sponsor of this study.

INTRODUCTION AND OBJECTIVE

A stepwise study in healthy volunteers to determine the static Sun Protection Factor (SPF) against the full solar ultraviolet (UV) spectrum (290 – 400 nm) of four Sun Protection products. Static SPF was determined without water immersion. Sunscreen protection against the full solar ultraviolet (UV) spectrum (290 - 400 nm) was measured and expressed as the Sun Protection Factor (SPF).

This study protocol followed the procedure outlined in the FDA Sunscreen Final Rule; 21 CFR Parts 201 and 310 [Docket No. FDA-1978-N-0018] (formerly Docket No. 1978N-0038), RIN 0910-AF43, Labelling and Effectiveness Testing; Sunscreen Drug Products for Over-the Counter Human Use [FR Doc. 2011-14766 Filed 06/16/2011; Publication Date: 06/17/2011].

MATERIALS AND METHODS

1. STUDY DESIGN

The study was conducted single blind, in a single centre.

A total of 10 subjects were dosed with the test articles.

2. SELECTION OF SUBJECTS

2.1. SCREENING

A total of ten subjects were recruited into the study that satisfied the following inclusion and exclusion criteria, and who were prepared to accept the prohibitions and restrictions and who gave written informed consent (Appendices 1 and 2).

The suitability of each potential subject was confirmed before their acceptance by review of a study specific pre-treatment questionnaire (Appendix 3).

2.2. INCLUSION CRITERIA

- a. Healthy male and female volunteers aged 18 years and older.
- b. Self-assessed skin type I (always burn easily; never tans), II (always burns easily; tans minimally) or III (burns moderately; tans gradually), according to the Fitzpatrick scale based on first 30 to 45 minutes sun exposure after a winter season of no sun exposure.
- c. Completed written informed consent.

2.3. EXCLUSION CRITERIA

- a. Pregnancy or lactation.
- b. Inadequate precautions/procedures to prevent pregnancy (women of childbearing potential only).

- c. A current skin disease of any type apart from mild acne
- d. Heavy alcohol consumption (i.e. more than 21 units per week or 8 units a day for men, more than 14 units per week or 4 units a day for women).
- e. Significant past medical history of hepatic, renal, cardiac, pulmonary, digestive, haematological, neurological disease.
- f. A history of multiple drug hypersensitivity.
- g. Concomitant medication associated with photosensitivity reactions, or which is likely to affect the response of the test articles or confuse the results of the study.
- h. Presence of uneven skin tones, pigmentation, scarring, or having excessive hair on the back (or are unwilling to have the hair clipped) that would interfere with the interpretation of the results.
- i. Greater than 10 naevi or other skin lesions on the back, which mean that these would be exposed to UV light.
- j. A high number of naevi (arbitrarily assigned as >100) on the body.
- k. Participation in a Sun Protection Factor test (SPF test) or follow-up work within the last 2 months.
- l. Subject has exhibited sensitization or questionable sensitization in an SPF test.
- m. Previous history of skin tumours/malignancy.
- n. Regular UVA sunbed users.
- o. A history of abnormal response to the sun.

2.4. PROHIBITIONS AND RESTRICTIONS

- a. Discontinuation of aspirin or non-steroidal anti-inflammatory medication for the duration of the study.
- b. Discontinuation of sun bed or sun lamp use, and avoidance of exposure of the test sites to natural sunlight for the duration of the study.

3. MATERIALS

3.1. TEST ARTICLES

The Sponsor provided the ingredient listings (Appendix 4) and certified that the products supplied to [REDACTED] [REDACTED] for the clinical trial had been manufactured/formulated with ingredients that are safe and suitable for the product's stated purpose.

The 7% Padimate O / 3% Oxybenzone Standard was used as a control.

The Sponsor confirmed the test article(s) do not contain antibiotics, antiseptics, steroids, hormones, or any other substances at levels of concentration requiring label declaration by the relevant regulatory authorities.

The following sunscreen preparations were tested:

1. Lipshade 100% Mineral SPF 30 (Shade #4)
2. Lipshade 100% Mineral SPF 30 (Shade #3)
3. Lipshade 100% Mineral SPF 30 (Shade #2)
4. Lipshade 100% Mineral SPF 30 (Shade #1)

It was the responsibility of the Sponsor to determine, for each batch of test article, the identity, strength, purity, composition, and other characteristics which appropriately defined the test article before its use in the study. The determination of its stability and documentation of methods of synthesis and derivation were also the Sponsor's responsibility.

It was the responsibility of the Sponsor that the test articles met all necessary transport regulations, particularly those regulations involving the carriage of hazardous goods and the import/export of goods, and that any costs including tax/duty are fully met by the Sponsor prior to receipt of the test article at [REDACTED]. No liability with regard to safe receipt or costs involved in carriage of goods to any [REDACTED] site would have been accepted.

On study completion, any remaining unused test articles were disposed of, unless otherwise requested by the Sponsor, after issuance of the final report or 28 days after study completion, whichever came first. Sponsors requesting the return of products were liable for any costs incurred.

4. METHOD

4.1. ARTIFICIAL LIGHT SOURCE

UV radiation was obtained from a 300W multiport solar simulator Model 601 V2.5 (Solar Light Company, Glenside PA). The unit was allowed to warm up for 20 minutes before use.

The % RCEE (relative cumulative erythemal effectiveness) limits were as follows:

WAVELENGTH (nm)	% RCEE ACCEPTANCE LIMIT
<290	<0.1
290-300	1.0-8.0
290-310	49.0-65.0
290-320	85.0-90.0
290-330	91.5-95.5
290-340	94.0-97.0
290-400	99.9-100.0

4.2. AMBIENT CONDITIONS

All procedures were performed in stable conditions at a temperature within the range of 18°C and 26°C.

4.3. INFORMED CONSENT, SCREENING AND TEST SITE IDENTIFICATION

On day 1 of the study, potential study participants reported to the testing facility for screening. Informed Consent was obtained, demographics collected, and study eligibility was confirmed. Test sites were checked for any conditions that could have affected evaluations or subject safety.

4.4. TREATMENT

4.4.1 MED (MINIMAL ERYTHEMAL DOSE) DETERMINATION

Each subject was treated with a series of five light exposures in order to determine the MED for unprotected skin. Each exposure time was 1.25 times greater than the previous one.

The MED study area was outlined on the lower back between waist and scapula and lateral to the midline. Subjects were exposed sat upright in a backless chair and the test sites outlined while the subject was in this position.

A template of the study area containing five subsites, each 3 cm x 2.5 cm, were marked on the back. The template was located ensuring that no moles or skin lesions were present in any of these subsites. Only the subsites were exposed. A record of individual exposure times and subsites was kept. After test exposure any immediate skin responses were noted and subjects were instructed to keep the test area covered from sunlight or other sources of UV light for the next 24 hours before they returned to the study centre.

4.4.2 MED ASSESSMENT

Subsites were graded 20±4 (16 to 24) hours after the MED exposure. The MED was assessed as being the lowest dose that elicited minimally perceptible erythema at a subsite (see Section 4.4.1).

4.4.3 TEST ARTICLE SPF (STATIC) DETERMINATION

Six test areas (each area consisting of test site square $\geq 30 \text{ cm}^2$ divided into test subsite areas $\geq 0.5 \text{ cm}^2$ with approximately 0.8 cm distance between subsites) were outlined on the back between shoulder blade and shoulder and parallel to the midline, above the MED test area.

The areas were located ensuring that no moles or skin lesions were present in any of these subsites. To one area was applied the SPF standard preparation

(7% Padimate O / 3% Oxybenzone Standard), one area remained untreated to re-determine the MED and the test articles were applied to the remaining test site areas. The test articles were applied by pipette by one technician at a dose of 2 mg or 2 µl per cm² (±2.5%) and spread over the five subsites with a gloved finger, which had been pre-saturated with the test article being applied.

Test article application was timed so that the UV exposures commenced 15 minutes to 30 minutes after application. Subjects were exposed sitting upright in a backless chair. Only the subsites were exposed. A record of individual exposure times and subsites was kept.

The UV exposures for test products and PADIMATE O/OXYBENZONE SPF STANDARD were calculated from previously determined MED (US) and the intended SPF. For products with an expected SPF less than 8, the exposures were MED_u times 0.64x, 0.80x, 1.00x, 1.25x and 1.56x. For products with an expected SPF between 8 and 15, the exposures were 0.69x, 0.83x, 1.00x, 1.20x and 1.44x. For products with an expected SPF greater than 15, the exposures were MED_u times 0.76x, 0.87x, 1.00x, 1.15x and 1.32x where x equals the expected SPF of the product.

Subjects were instructed to keep the test areas covered from sunlight or other sources of UV light for the next 24 hours and to return to the study centre after this time for assessment.

4.4.4 SPF DETERMINATION

The SPF values of the test articles were determined (see Section 4.4.5).

4.4.5 SPF ASSESSMENT AND CALCULATION

Determination of the Test Product's SPF Value:

Sixteen to twenty-four hours post-exposure, the subjects returned to the testing facility for visual evaluation of erythema responses. The trained technician who evaluated the MED did not know the identity of the test product application sites and UV exposures. Also, he/she was not the same person to have applied the sunscreen product to the test site or administered the doses of UV radiation.

Calculation of SPF:

SPF value for each test subject (SPF_i) was calculated as follows:

$$SPF_i = \frac{MED_p}{MED_u}$$

Where MED_p is the “protected” result divided by the MED_u is the “unprotected” result.

Calculate the mean SPF and the standard deviation (s) from the SPF_i values.

Calculate the standard error (SE) which equals s/\sqrt{n} where n = the number of subjects who provided valid test results.

$$SE = \frac{s}{\sqrt{n}}$$

The upper 5% point (A) will be obtained from the Student's t distribution table with n-1 degrees of freedom (t). A will be calculated as follows:

$$A = t \cdot SE$$

The label SPF for panels using a minimum of 10 evaluable subjects is the largest whole number less than the mean SPF minus A. In order for the SPF determination of a test product to be considered valid, the SPF value of the SPF standard should fall within the standard deviation range of the expected SPF (i.e., 16.3 ± 3.43).

$$\text{Label SPF} = \overline{SPF} - A$$

4.5. SKIN ASSESSMENT

assessed all skin on all days, whilst the subject was standing, in a room with natural wall colour. Illumination of the study areas was by means of a 60-Watt pearl bulb at a distance from the study area of approximately 30 cm.

The following grading scale was used:

- 0.0 = no perceptible erythema
- 0.5 = ambiguous erythema or not having clear borders
- 1.0 = minimally perceptible erythema having clear border (MED)
- 2.0 = moderate erythema
- 3.0 = severe erythema with edema

The series of UV-exposures should produce at least a first subsite without erythema (grade of 0.0) and one or more sites with responses ranging from minimal erythema to well-defined erythema. The lowest UV dose producing the endpoint of minimal erythema determines the individual's MED (grade 1.0).

Any instance of painful erythema or severe erythema with a grade of 3 or greater was considered an adverse experience.

5. STUDY ETHICS

5.1 DECLARATION OF HELSINKI

The study will conform to the requirements of the 1964 Declaration of Helsinki and its subsequent amendments (World Medical Association; 2013).

5.2 INDEMNITY PROVISION

The Sponsor shall be responsible, without regard to legal liability, and shall indemnify [REDACTED], or any of their respective officers or employees in the event of claims for compensation from subjects suffering injury arising out of the administration or use of the test article, or of any procedure required under this protocol as a result of a subject participating in this study, except and insofar as such claims arise as a result of any negligent act or omission on the part of [REDACTED] employees or any persons undertaking or involved in the study by arrangement with [REDACTED].

6. QUALITY ASSURANCE

The study will be carried out within the spirit of the ICH Guidelines on Good Clinical Practice (ICH E6_R2) and other recognised guidelines. An audit of the final report will be completed, for accuracy and completeness of presentation. Additionally, the study may be subject to the following Quality Assurance procedures:

- Review of protocol and protocol amendments for completeness, clarity and adequacy.
- Inspection and/or audit of critical phases of study conduct for compliance with protocol and [REDACTED] procedures.

[REDACTED] Quality Assurance will inform [REDACTED] management of any findings that may affect the integrity of the study.

7. RETENTION OF DATA

All raw data generated by [REDACTED] during the course of the study, and including protocol and final report, will be retained in the [REDACTED] Archive for a minimum period of five years from study completion. In the event of original data being transferred to the Sponsor at their request, exact copies will be so retained. At no time will archived data be destroyed without prior written approval of the Sponsor. All study data will be available at any time, by appointment, for inspection by the Sponsor or their authorised representative.

8. REFERENCES

1. ICH E6_R2, INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE, Current Step 4 version dated 9 November 2016.
2. FDA 21 CFR Parts 201 and 310 Sunscreen Drug Products for Over-the-Counter Human Use; Labelling and Effectiveness Testing [Docket no. FDA-1978-N-0018] (Formerly Docket No. 1978N-0038) RIN 0910-AF43.
3. The validity and practicability of sun-reactive skin types I through IV. Archives Dermatol. 124 p. 869-871 (1988).
4. World Medical Association (2013). "Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects". JAMA 310 (20): 2191–2194. doi:10.1001/jama.2013.281053

RESULTS

1 LOCATION AND DATES OF THE STUDY

The study was performed at [REDACTED], between w/c 6th June 2022 and w/e 10th June 2022, and between w/c 4th July 2022 and w/e 8th July 2022.

2 SUBJECTS

10 subjects of both sexes were recruited into and completed the study.

[REDACTED] Demographics

Subject	Tech Initials	Age	Gender	Ethnicity	Fitzpatrick	MED
1	AK	53	Male	CAUCASIAN	I	19
2	AK	18	Male	CAUCASIAN	III	32
3	AK	36	Female	CAUCASIAN	III	35
4	AK	41	Male	CAUCASIAN	II	21
5	AK	31	Female	CAUCASIAN	III	26
6	AK	51	Female	CAUCASIAN	III	28
7	AK	27	Female	CAUCASIAN	I	17
8	AK	57	Male	CAUCASIAN	II	24
9	AK	23	Female	CAUCASIAN	II	20
10	AK	24	Male	CAUCASIAN	I	18

3 ADVERSE EVENTS, ADVERSE REACTIONS AND SUBJECTS NOT COMPLETING THE STUDY

No adverse events or reactions were reported, no subjects withdrew. The study was completed by all 10 subjects.

4 QUALITY OF UV IRRADIATION

The percentage RCEE (relative cumulative erythemal effectiveness) for the solar simulator used in this study was within the acceptable lower and upper limits directed by the FDA Sunscreen Final Rule; 21 CFR Parts 201 and 310 SPF test methods - In vivo determination of Sun Protection Factor (SPF).

5 ASSESSMENTS

Individual and mean SPF values, their standard deviations and confidence intervals for all 10 subjects are presented in Tables 1 to 5.

The static SPF value for the standard preparation was 16.33 (Label SPF = 15). The study can therefore be considered valid.

RESULTS

Mean Static SPF results (N=10) for the test articles:

Test article 1 – Lipshade 100% Mineral SPF 30 () achieved a mean SPF value of 33.15. The calculated Label SPF = 31.

Test article 2 – Lipshade 100% Mineral SPF 30 (Shade #3) achieved a mean SPF value of 33.60. The calculated Label SPF = 32.

Test article 3 – Lipshade 100% Mineral SPF 30 (Shade #2) Expected SPF30) achieved a mean SPF value of 33.15. The calculated Label SPF = 31.

Test article 4 – Lipshade 100% Mineral SPF 30 (Shade #1) achieved a mean SPF value of 33.15. The calculated Label SPF = 31.

Table 1 – INDIVIDUAL AND MEAN SPF VALUES FOR TEST ARTICLE 1 – Lipshade 100% Mineral SPF 30 (Shade #4)

1 - Lipshade 100% Mineral SPF 30 (Shade #4)		SITE	1			2			3			4			5			Re-determined MED	Individual SPF
SUB NO	MED	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE			
1	19	431	3448	0.0	496	3965	0.0	570	4560	0.5	656	5244	1.0	754	6031	2.0	19	34.50	
2	32	726	5807	0.0	835	6678	0.0	960	7680	0.0	1104	8832	1.0	1270	10157	1.0	32	34.50	
3	35	794	6352	0.0	913	7304	0.0	1050	8400	1.0	1208	9660	2.0	1389	11109	2.0	35	30.00	
4	21	476	3811	0.0	548	4383	0.0	630	5040	0.0	725	5796	1.0	833	6665	1.0	21	34.50	
5	26	590	4718	0.0	678	5426	0.0	780	6240	0.0	897	7176	1.0	1032	8252	1.0	26	34.50	
6	28	635	5081	0.0	730	5843	0.0	840	6720	0.5	966	7728	1.0	1111	8887	2.0	28	34.50	
7	17	386	3085	0.0	443	3548	0.0	510	4080	1.0	587	4692	1.0	674	5396	2.0	17	30.00	
8	24	544	4355	0.0	626	5009	0.0	720	5760	1.0	828	6624	1.0	952	7618	2.0	24	30.00	
9	20	454	3629	0.0	522	4174	0.0	600	4800	0.0	690	5520	1.0	794	6348	1.0	20	34.50	
10	18	408	3267	0.0	470	3757	0.0	540	4320	0.0	621	4968	1.0	714	5713	1.0	18	34.50	
Mean																		33.15	
Std Dev																		2.17	
SE																		0.69	
95% CI																		1.55	
Label SPF calculated																		31.59	

Table 2 – INDIVIDUAL AND MEAN SPF VALUES FOR TEST ARTICLE 2 – Lipshade 100% Mineral SPF 30 (Shade #3)

2 - Lipshade 100% Mineral SPF 30 (Shade #3)		SITE	1			2			3			4			5			Re-determined MED	Individual SPF
SUB NO	MED	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE			
1	19	431	3448	0.0	496	3965	0.0	570	4560	0.0	656	5244	1.0	754	6031	1.0	19	34.50	
2	32	726	5807	0.0	835	6678	0.0	960	7680	0.0	1104	8832	1.0	1270	10157	1.0	32	34.50	
3	35	794	6352	0.0	913	7304	0.0	1050	8400	0.0	1208	9660	1.0	1389	11109	1.0	35	34.50	
4	21	476	3811	0.0	548	4383	0.0	630	5040	1.0	725	5796	1.0	833	6665	2.0	21	30.00	
5	26	590	4718	0.0	678	5426	0.0	780	6240	0.0	897	7176	1.0	1032	8252	1.0	26	34.50	
6	28	635	5081	0.0	730	5843	0.0	840	6720	0.0	966	7728	1.0	1111	8887	1.0	28	34.50	
7	17	386	3085	0.0	443	3548	0.0	510	4080	1.0	587	4692	2.0	674	5396	2.0	17	30.00	
8	24	544	4355	0.0	626	5009	0.0	720	5760	0.0	828	6624	1.0	952	7618	1.0	24	34.50	
9	20	454	3629	0.0	522	4174	0.0	600	4800	0.0	690	5520	1.0	794	6348	1.0	20	34.50	
10	18	408	3267	0.0	470	3757	0.0	540	4320	0.5	621	4968	1.0	714	5713	2.0	18	34.50	
Mean																		33.60	
Std Dev																		1.90	
SE																		0.60	
95% CI																		1.36	
Label SPF calculated																		32.24	

Table 3 – INDIVIDUAL AND MEAN SPF VALUES FOR TEST ARTICLE 3 – Lipshade 100% Mineral SPF 30 (Shade #2)

3 - Lipshade 100% Mineral SPF 30 (Shade #2)		SITE	1			2			3			4			5			Re-determined MED	Individual SPF
SUB NO	MED	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE			
1	19	431	3448	0.0	496	3965	0.0	570	4560	0.0	656	5244	1.0	754	6031	1.0	19	34.50	
2	32	726	5807	0.0	835	6678	0.0	960	7680	0.0	1104	8832	1.0	1270	10157	1.0	32	34.50	
3	35	794	6352	0.0	913	7304	0.0	1050	8400	0.0	1208	9660	1.0	1389	11109	1.0	35	34.50	
4	21	476	3811	0.0	548	4383	0.0	630	5040	0.5	725	5796	1.0	833	6665	2.0	21	34.50	
5	26	590	4718	0.0	678	5426	0.0	780	6240	1.0	897	7176	1.0	1032	8252	2.0	26	30.00	
6	28	635	5081	0.0	730	5843	0.0	840	6720	0.0	966	7728	1.0	1111	8887	1.0	28	34.50	
7	17	386	3085	0.0	443	3548	0.0	510	4080	0.5	587	4692	1.0	674	5396	2.0	17	34.50	
8	24	544	4355	0.0	626	5009	0.0	720	5760	0.0	828	6624	1.0	952	7618	1.0	24	34.50	
9	20	454	3629	0.0	522	4174	0.0	600	4800	1.0	690	5520	1.0	794	6348	2.0	20	30.00	
10	18	408	3267	0.0	470	3757	0.0	540	4320	1.0	621	4968	1.0	714	5713	2.0	18	30.00	
Mean																		33.15	
Std Dev																		2.17	
SE																		0.69	
95% CI																		1.55	
Label SPF calculated																		31.59	

Table 4 – INDIVIDUAL AND MEAN SPF VALUES FOR TEST ARTICLE 4 – Lipshade 100% Mineral SPF 30 (Shade #1)

4 - Lipshade 100% Mineral SPF 30 (Shade #1) (15N9439M)		SITE	1			2			3			4			5			Re-determined MED	Individual SPF
SUB NO	MED	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE	TIME (SECS)	J/m2 eff	GRADE			
1	19	431	3448	0.0	496	3965	0.0	570	4560	1.0	656	5244	1.0	754	6031	2.0	19	30.00	
2	32	726	5807	0.0	835	6678	0.0	960	7680	0.5	1104	8832	1.0	1270	10157	2.0	32	34.50	
3	35	794	6352	0.0	913	7304	0.0	1050	8400	0.0	1208	9660	1.0	1389	11109	1.0	35	34.50	
4	21	476	3811	0.0	548	4383	0.0	630	5040	0.0	725	5796	1.0	833	6665	1.0	21	34.50	
5	26	590	4718	0.0	678	5426	0.0	780	6240	1.0	897	7176	1.0	1032	8252	2.0	26	30.00	
6	28	635	5081	0.0	730	5843	0.0	840	6720	0.0	966	7728	1.0	1111	8887	1.0	28	34.50	
7	17	386	3085	0.0	443	3548	0.0	510	4080	0.0	587	4692	1.0	674	5396	1.0	17	34.50	
8	24	544	4355	0.0	626	5009	0.0	720	5760	0.0	828	6624	1.0	952	7618	1.0	24	34.50	
9	20	454	3629	0.0	522	4174	0.0	600	4800	1.0	690	5520	2.0	794	6348	2.0	20	30.00	
10	18	408	3267	0.0	470	3757	0.0	540	4320	0.0	621	4968	1.0	714	5713	1.0	18	34.50	
Mean																		33.15	
Std Dev																		2.17	
SE																		0.69	
95% CI																		1.55	
Label SPF calculated																		31.59	

Table 5 – INDIVIDUAL AND MEAN SPF VALUES FOR FDA SPF standard preparation (7% padimate, 3% oxybenzone)

5 - Standard Reference SPF (7% padimate, 3% oxybenzone) SPF 16.3		1			2			3			4			5			Re-determined MED	Individual SPF
SUB NO	SITE	TIME (SECS)	J/cm2 eff	GRADE	TIME (SECS)	J/cm2 eff	GRADE	TIME (SECS)	J/cm2 eff	GRADE	TIME (SECS)	J/cm2 eff	GRADE	TIME (SECS)	J/cm2 eff	GRADE		
1	19	234	1873	0.0	269	2154	0.0	310	2478	1.0	356	2849	1.0	410	3277	2.0	19	16.30
2	32	394	3155	0.0	454	3629	0.0	522	4173	1.0	600	4799	2.0	690	5519	2.0	32	16.30
3	35	431	3451	0.0	496	3969	0.0	571	4564	1.0	656	5249	1.0	754	6036	2.0	35	16.30
4	21	259	2071	0.0	298	2381	0.0	342	2738	0.5	394	3149	1.0	453	3622	2.0	21	18.75
5	26	320	2564	0.0	369	2948	0.0	424	3390	1.0	487	3899	1.0	560	4484	2.0	26	16.30
6	28	345	2761	0.0	397	3175	0.0	456	3651	1.0	525	4199	1.0	604	4829	2.0	28	16.30
7	17	210	1676	0.0	241	1928	0.0	277	2217	1.0	319	2549	1.0	366	2932	2.0	17	16.30
8	24	296	2366	0.0	340	2721	1.0	391	3130	1.0	450	3599	2.0	517	4139	2.0	24	14.17
9	20	247	1972	0.0	283	2268	0.0	326	2608	1.0	375	2999	1.0	431	3449	2.0	20	16.30
10	18	222	1775	0.0	255	2041	0.0	293	2347	1.0	337	2699	1.0	388	3104	2.0	18	16.30
Mean																		16.33
Std Dev																		1.08
SE																		0.34
95% CI																		0.77
Label SPF calculated																		15.56

APPENDIX 1: CONSENT FORM

Study Code: SUPSPF23C

Subject #: _____

INTRODUCTION

You are being asked to participate in a research study. Prior to giving your consent to be a subject, it is important that you take the time to read and understand what your participation would involve. This consent form may contain technical language which you may not understand. If you do not understand any of this consent form, please ask the clinical staff any questions you may have.

You will be provided with a signed copy of this consent form and any other necessary written information prior to the start of the study.

OBJECTIVE

The objective of this research study is to determine the sun protection factor (SPF) of four test articles after exposure to simulated sunlight (UV light).

TEST ARTICLES

The test articles applied by study staff to designated test sites located on the back.

STUDY PROCEDURES

You will be one of approximately 10 subjects enrolled onto this study. Your participation in this study will last approximately four days and will include four visits to the testing facility.

Visit 1 (Study Day 1): Prior to acceptance on the study, you will be consented and screened for eligibility to participate on the study. You will be supplied with a gown to wear, as we need to see your back. We will mark out five squares, 2.5 cm x 3 cm on your back and whilst you sit upright on a backless chair, we will expose these squares to UV light from a special sunlamp. Each square will be exposed to simulated sunlight for a different length of time so that we can find out the time needed to produce a faint pinkness (slight skin redness).

Visit 2 (Study Day 2): You will be supplied with a gown to wear. We will assess the degree of pinkness to the sites previously exposed to the artificial sunlight. We may need to expose a new area of your back to the same type of simulated sunlight (UV light) to determine the more exact time to produce this faint pinkness.

Visit 3 (Study Day 3): We will assess your back on this day. We will then mark out areas on your back. On these different areas we will apply the test products and one area will remain untreated. We will then expose five squares 2.5 cm x 3 cm per test area to UV light for different times depending on your skin sensitivity. These times are equivalent to up to a day's natural sun exposure depending on the expected SPF of the product.

Visit 4 (Study Day 4): We will assess your back on this day.

RISKS

To the best of our knowledge, these products are not expected to induce an allergic reaction. While the potential for irritation or other reactions during this study are minimal, it is possible for a reaction to occur. Expected reactions for these test articles categories are mild in nature and may include the following: redness, itching, peeling or blistering. You will have slight redness to your skin (like a mild sunburn) only in the areas exposed to the artificial (simulated) sunlight. In addition to the risks described, there may be other risks that are currently unforeseeable.

No significant adverse reactions are expected to occur. However, if you develop an adverse reaction or complication as a result of your participation in this study, medical treatment will be provided by clinical staff nurses at [REDACTED] or you will be referred for appropriate treatment at no cost to you, as long as you have followed the study instructions. Provisions of such medical care is not an admission of legal responsibility.

You will be followed by [REDACTED] until the adverse reaction has resolved. No additional compensation will be available to you. Neither the sponsoring company nor the investigating company will be held responsible for any future medical expenses.

BENEFITS

While it is likely that you will not receive any direct benefit from your participation in the study, the study results may have the potential to increase scientific knowledge about skincare products and may allow for new and improved products to be marketed.

CONFIDENTIALITY

Information concerning you that is obtained in connection with this study will be kept confidential by [REDACTED], except that the sponsoring company whose products are being tested will receive a copy of the study records. The data will be uniquely coded to protect your identity. In addition, the study investigator, third party regulatory authorities, including the U.S. Food and Drug Administration (FDA), IRB/IEC or the sponsor (including monitors and auditors), may inspect the records of the study. Therefore, total privacy cannot be guaranteed.

Your signature on the Informed Consent provides your permission for these agencies to view your personal information and the study data.

IN CASE OF STUDY RELATED INJURY

If you are injured while participating in this study, [REDACTED] will provide you with treatment. If your illness or injury is the result of the study products or any procedure required by the study that you would not have undergone were it not for your participation in the study, the sponsor will pay usual and customary medical fees for reasonable and necessary treatment, provided you have not already otherwise been properly reimbursed by your insurance, a government program, or other third-party coverage for such medical expenses. The sponsor is not responsible for expenses that are due to pre-existing medical conditions, underlying disease, procedures which would have been performed even if you were not participating in the study, your negligence or wilful misconduct, or the negligence or wilful misconduct of institution, principal investigators, or third parties. No funds have been set aside by the sponsor to compensate you for lost wages, disability, or discomfort due to your participation in this study. You do not give up any legal rights as a research participant by signing this consent form.

COMPENSATION FOR INJURY

No significant adverse reactions are expected to occur. However, if you develop an adverse reaction or complication as a result of your participation in this study, medical treatment will be provided by clinical study staff at [REDACTED], or you will be referred for appropriate treatment at no cost to you. Provisions of such medical care are not an admission of legal responsibility. You will be followed by [REDACTED] until the adverse reaction has resolved. No additional compensation will be available to you. Neither the sponsoring company nor the investigating company will be held responsible for any future medical expenses.

In no way does signing this consent form waive your legal rights nor does it relieve the investigators, Sponsor or involved institutions from their legal and professional responsibilities.

FEMALES OF CHILDBEARING POTENTIAL

Pregnant and/or nursing women may not take part in this study. Signing and dating this consent form means that you are stating that you are not pregnant, planning a pregnancy, or nursing at the start of the study.

The test products may involve unknown risks to you, your nursing infant, or your unborn child if you become pregnant while on the study. By signing this form, you agree to practice an acceptable method of birth control for the duration of the study.

NEW FINDINGS

Any new information that is discovered during the study and which may influence your willingness to continue in the study will be made available to you.

MEDICAL TREATMENT

In the event of an emergency, dial 999. If you receive any medical care during the course of the study, inform medical personnel that you are participating in a research study. Please contact [REDACTED] staff as soon as possible to inform them of your condition.

CONTACT

If you have any questions about this study or in the case of an emergency, contact [REDACTED] [REDACTED] during normal business hours.

VOLUNTARY PARTICIPATION/WITHDRAWAL

Your participation in this research study is strictly voluntary. You may refuse to participate or may discontinue participation at any time during the study without penalty or loss of benefits to which you are otherwise entitled. However, you must contact the test facility and inform a clinical staff member of your decision to withdraw from the study.

If you agree to participate in the study, you are also agreeing to provide [REDACTED] with accurate information and to follow study instructions as given to you. If you fail to follow study instructions, you may be asked to discontinue participation.

Your participation in the study may be discontinued at any time without your consent by [REDACTED] [REDACTED] regulatory agencies, or the sponsoring company for reasons of but not limited to a severe side effect and accompanying illness, or if you do not follow study instructions.

NON-DISCLOSURE

As a condition to your participation in the study you are asked not to discuss any information regarding the products that you are testing, your experiences with the products, or your opinion of the products with anyone outside of the testing facility. By your signature on the Consent you are agreeing to abide by this condition of participation.

PHOTOGRAPHY AUTHORIZATION

As an additional part of this study, study staff may take photographs or videotape during the study. These photos or videos may be used for the following purposes: training of [REDACTED] [REDACTED] documentation of study procedures/results or upon request of the sponsor. By signing this consent form, you are giving your authorization for [REDACTED] to take, use, reproduce, and distribute these photographs/videotapes taken during your participation in this study.

COMPENSATION

If you agree to participate in this study, you will be paid £XX upon completion of the study.

CONSENT TO PARTICIPATE

I know that my participation in this study is voluntary and that I have the right to refuse to participate. I know that I may withdraw from the study at any time without penalty or loss of benefits to which I am otherwise entitled. If, at the discretion of the Investigator, it is best to discontinue my participation for reasons other than a failure to obey the directions of the study, I will be paid in full or for the portion of the study I have completed once the study is over.

CONSENT

I have read all of the pages of this consent form and have been given an opportunity to ask questions about this study. Answers to such questions (if any) were satisfactory. I am at least eighteen years old and without reservation give my consent to serve as a subject in this study.

By signing this form, I have not given up any of my legal rights as a research subject. I will receive a copy of this signed consent document.

You are making a decision whether or not to participate. Your signature indicates that you have decided to participate, having read the information provided above.

Subject's Name Printed: First

Middle Initial

Last

Subject's Signature

Date

Signature of Person Conducting Consent Discussion

Date

Subject Number

APPENDIX 2: SUBJECT INFORMATION SHEET

Subject No.: _____

You have agreed to participate in a research study. By agreeing to participate, you are also agreeing to the following prohibitions and restrictions:

- Discontinuation of aspirin or non-steroidal anti-inflammatory medication for the duration of the study.
- Discontinuation of sun bed or sun lamp use, and avoidance of exposure of the test sites to natural sunlight for the duration of the study.
- Prevention of test areas from getting wet for the duration of the study.

Study schedule:

Monday	Tuesday	Wednesday	Thursday
6 th June (Subjects 1 – 5)	7 th June (Subjects 1 – 5)	8 th June (Subjects 1 – 5)	9 th June (Subjects 1 – 5)
4 th July (Subjects 6 - 10)	5 th July (Subjects 6 - 10)	6 th July (Subjects 6 - 10)	7 th July (Subjects 6 - 10)
Visit 1	Visit 2	Visit 3	Visit 4
Baseline measure.	Assessment of the degree of pinkness to the skin.	Assessment of the degree of pinkness to the skin where necessary.	Assessment of the degree of pinkness to the skin.
Area of the back to be exposed to UV light for different lengths of time to produce a faint pinkness to the skin.	(A new area of skin on the back may then be exposed to UV light for a more exact time to produce a faint pinkness to the skin.)	Six test areas will be marked out on your back, the test articles applied and then exposed to UV light for different times depending on your skin sensitivity.	Compensation

*You must come in for all visits; no misses will be allowed. If you are unable to come in for a visit, your participation will be discontinued.

Upon completion of this study on 9th June or 7th July 2022, you will receive £XX for your participation.

If you have any questions about this study or in the case of a suspected allergic reaction, call _____ during normal business hours.

APPENDIX 3: PRE-TREATMENT QUESTIONNAIRE

Subject No. _____

FOR OFFICE USE ONLY		
Subject's Initials		
Subject's DOB: _____	Subject's Age: _____	
MALE/FEMALE		

STRICTLY CONFIDENTIAL

Inclusion Criteria (NO – Exclude)		Yes	No
1.	Subject is a healthy male or female, aged 18 years or older.	<input type="checkbox"/>	<input type="checkbox"/>
2.	Subject has self-assessed skin type I (always burns easily; never tans), II (always burns easily; tans minimally) or III (burns moderately; tans gradually), according to the Fitzpatrick scale based on first 30 to 45 minutes sun exposure after a winter season of no sun exposure.	<input type="checkbox"/>	<input type="checkbox"/>
3.	Subject has signed a written informed consent.	<input type="checkbox"/>	<input type="checkbox"/>
Exclusion Criteria (YES – Exclude)		Yes	No
1.	Subject is pregnant, nursing, or planning to become pregnant. Male N/A <input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2.	Subject is using an inadequate method of birth control.	<input type="checkbox"/>	<input type="checkbox"/>
3.	Subject reports a current skin disease of any type apart from mild facial acne.	<input type="checkbox"/>	<input type="checkbox"/>
4.	Subject has heavy alcohol consumption (i.e. more than 21 units/week or 8 units/day for men, more than 14 units/week or 4 units/day for women).	<input type="checkbox"/>	<input type="checkbox"/>
5.	Subject has a significant past medical history of hepatic, renal, cardiac, pulmonary, digestive, haematological or neurological disease.	<input type="checkbox"/>	<input type="checkbox"/>
6.	Subject has a history of multiple drug hypersensitivity.	<input type="checkbox"/>	<input type="checkbox"/>
7.	Subject is taking concomitant medication associated with photosensitivity reactions which is likely to affect the response of the test articles or confuse the results of the study.	<input type="checkbox"/>	<input type="checkbox"/>
8.	Presence of uneven skin tones, pigmentation, scarring, or having excessive hair on the back (or are unwilling to have the hair clipped) that would interfere with the interpretation of the results.	<input type="checkbox"/>	<input type="checkbox"/>
9.	Subject has greater than 10 naevi or other skin lesions on the back, which mean that these would be exposed to UV light.	<input type="checkbox"/>	<input type="checkbox"/>
10.	Subject has a high number of naevi (arbitrary assigned a >100) on the body.	<input type="checkbox"/>	<input type="checkbox"/>
11.	Subject has participated in a Sun Protection Factor test (SPF test) or follow-up work within the last 2 months.	<input type="checkbox"/>	<input type="checkbox"/>
12.	Subject has exhibited sensitization or questionable sensitization in an SPF test.	<input type="checkbox"/>	<input type="checkbox"/>
13.	Subject has a history of skin tumours.	<input type="checkbox"/>	<input type="checkbox"/>
14.	Subject is a regular sunbed user.	<input type="checkbox"/>	<input type="checkbox"/>
15.	Subject has a history of abnormal response to the sun.	<input type="checkbox"/>	<input type="checkbox"/>

Prohibitions and Restrictions (NO – Exclude)		Yes	No
1.	Subject agrees to discontinue use of aspirin or non-steroidal anti-inflammatory medication for the duration of the study.	<input type="checkbox"/>	<input type="checkbox"/>
2.	Subject agrees to discontinue use of sun beds or sun lamps, and to avoid exposure of the test sites to natural sunlight for the duration of the study.	<input type="checkbox"/>	<input type="checkbox"/>

Have you ever had any skin problems related to the use of any of the following types of material?

Material	Yes	No	When? – Which products? – What happens?
Sunscreen/SPF Products			
Other Personal Care Products – please specify			

Questionnaire checked and confirmed by:

Signature

Date

APPENDIX 4: TEST ARTICLE INGREDIENT LISTING**TEST ARTICLE 1 – Lipshade 100% Mineral SPF 30 (Shade #4)****ACTIVE INGREDIENTS**

ZINC OXIDE 17.5%

INGREDIENTS

RICINUS COMMUNIS (CASTOR) SEED OIL
 CAPRYLIC/CAPRIC TRIGLYCERIDE
 JOJOBA ESTERS
 EUPHORBIA CERIFERA (CANDELILLA) WAX
 PERSEA GRATISSIMA (AVOCADO) OIL
 BIS-DIGLYCERYL POLYACYLADIPATE-2
 FLAVOR (AROMA)
 SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL
 ARGANIA SPINOSA KERNEL OIL
 TOCOPHERYL ACETATE
 COPERNICIA CERIFERA (CARNAUBA) WAX
 STEVIOSIDE
 CETEARYL ETHYLHEXANOATE
 SYNTHETIC FLUORPHLOGOPITE
 ISOSTEARIC ACID
 LECITHIN
 POLYHYDROXYSTEARIC ACID
 POLYGLYCERYL-3 POLYRICINOLEATE
 BUTYROSPERMUM PARKII (SHEA) BUTTER
 MANGIFERA INDICA (MANGO) SEED BUTTER
 ASTROCARYUM MURUMURU SEED BUTTER
 CALCIUM SODIUM BOROSILICATE
 ROSA CANINA FRUIT OIL
 SORBITAN ISOSTEARATE
 BISABOLOL
 VACCINIUM MACROCARPON (CRANBERRY) SEED OIL
 PORTULACA PILOSA EXTRACT
 TOCOPHEROL
 ASCORBYL PALMITATE
 SUCROSE COCOATE
 GLYCINE SOJA (SOYBEAN) OIL
 PALMITOYL TRIPEPTIDE-38
 TIN OXIDE
 TITANIUM DIOXIDE (CI 77891)
 RED 28 LAKE (CI 45410)

MAY CONTAIN:

IRON OXIDES (CI 77491, 77942, 77499)
 YELLOW 5 LAKE (CI 19140)
 RED 7 LAKE (CI 15850)
 YELLOW 6 LAKE (CI 15985)
 BLUE 1 LAKE (CI 42090)

TEST ARTICLE 2 – LIPSHADE 100% MINERAL SPF 30 (SHADE #3)**ACTIVE INGREDIENTS**

ZINC OXIDE 17.5%

INGREDIENTS

RICINUS COMMUNIS (CASTOR) SEED OIL
CAPRYLIC/CAPRIC TRIGLYCERIDE
JOJOBA ESTERS
EUPHORBIA CERIFERA (CANDELILLA) WAX
PERSEA GRATISSIMA (AVOCADO) OIL
BIS-DIGLYCERYL POLYACYLADIPATE-2
FLAVOR (AROMA)
SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL
ARGANIA SPINOSA KERNEL OIL
TOCOPHERYL ACETATE
COPERNICIA CERIFERA (CARNAUBA) WAX
STEVIOSIDE
CETEARYL ETHYLHEXANOATE
SYNTHETIC FLUORPHLOGOPITE
ISOSTEARIC ACID
LECITHIN
POLYHYDROXYSTEARIC ACID
POLYGLYCERYL-3 POLYRICINOLEATE
BUTYROSPERMUM PARKII (SHEA) BUTTER
MANGIFERA INDICA (MANGO) SEED BUTTER
ASTROCARYUM MURUMURU SEED BUTTER
CALCIUM SODIUM BOROSILICATE
ROSA CANINA FRUIT OIL
SORBITAN ISOSTEARATE
BISABOLOL
VACCINIUM MACROCARPON (CRANBERRY) SEED OIL
PORTULACA PILOSA EXTRACT
TOCOPHEROL
ASCORBYL PALMITATE
SUCROSE COCOATE
GLYCINE SOJA (SOYBEAN) OIL
PALMITOYL TRIPEPTIDE-38
TIN OXIDE
TITANIUM DIOXIDE (CI 77891)
RED 28 LAKE (CI 45410)

MAY CONTAIN:

IRON OXIDES (CI 77491, 77942, 77499)
YELLOW 5 LAKE (CI 19140)
RED 7 LAKE (CI 15850)
YELLOW 6 LAKE (CI 15985)
BLUE 1 LAKE (CI 42090)

TEST ARTICLE 3 – LIPSHADE 100% MINERAL SPF 30 (SHADE #2)**ACTIVE INGREDIENTS**

ZINC OXIDE 17.5%

INGREDIENTS

RICINUS COMMUNIS (CASTOR) SEED OIL
CAPRYLIC/CAPRIC TRIGLYCERIDE
JOJOBA ESTERS
EUPHORBIA CERIFERA (CANDELILLA) WAX
PERSEA GRATISSIMA (AVOCADO) OIL
BIS-DIGLYCERYL POLYACYLADIPATE-2
FLAVOR (AROMA)
SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL
ARGANIA SPINOSA KERNEL OIL
TOCOPHERYL ACETATE
COPERNICIA CERIFERA (CARNAUBA) WAX
STEVIOSIDE
CETEARYL ETHYLHEXANOATE
SYNTHETIC FLUORPHLOGOPITE
ISOSTEARIC ACID
LECITHIN
POLYHYDROXYSTEARIC ACID
POLYGLYCERYL-3 POLYRICINOLEATE
BUTYROSPERMUM PARKII (SHEA) BUTTER
MANGIFERA INDICA (MANGO) SEED BUTTER
ASTROCARYUM MURUMURU SEED BUTTER
CALCIUM SODIUM BOROSILICATE
ROSA CANINA FRUIT OIL
SORBITAN ISOSTEARATE
BISABOLOL
VACCINIUM MACROCARPON (CRANBERRY) SEED OIL
PORTULACA PILOSA EXTRACT
TOCOPHEROL
ASCORBYL PALMITATE
SUCROSE COCOATE
GLYCINE SOJA (SOYBEAN) OIL
PALMITOYL TRIPEPTIDE-38
TIN OXIDE
TITANIUM DIOXIDE (CI 77891)
RED 28 LAKE (CI 45410)

MAY CONTAIN:

IRON OXIDES (CI 77491, 77942, 77499)
YELLOW 5 LAKE (CI 19140)
RED 7 LAKE (CI 15850)
YELLOW 6 LAKE (CI 15985)
BLUE 1 LAKE (CI 42090)

TEST ARTICLE 4 – LIPSHADE 100% MINERAL SPF 30 (SHADE #1)**ACTIVE INGREDIENTS**

ZINC OXIDE 17.5%

INGREDIENTS

RICINUS COMMUNIS (CASTOR) SEED OIL
CAPRYLIC/CAPRIC TRIGLYCERIDE
JOJOBA ESTERS
EUPHORBIA CERIFERA (CANDELILLA) WAX
PERSEA GRATISSIMA (AVOCADO) OIL
BIS-DIGLYCERYL POLYACYLADIPATE-2
FLAVOR (AROMA)
SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL
ARGANIA SPINOSA KERNEL OIL
TOCOPHERYL ACETATE
COPERNICIA CERIFERA (CARNAUBA) WAX
STEVIOSIDE
CETEARYL ETHYLHEXANOATE
SYNTHETIC FLUORPHLOGOPITE
ISOSTEARIC ACID
LECITHIN
POLYHYDROXYSTEARIC ACID
POLYGLYCERYL-3 POLYRICINOLEATE
BUTYROSPERMUM PARKII (SHEA) BUTTER
MANGIFERA INDICA (MANGO) SEED BUTTER
ASTROCARYUM MURUMURU SEED BUTTER
CALCIUM SODIUM BOROSILICATE
ROSA CANINA FRUIT OIL
SORBITAN ISOSTEARATE
BISABOLOL
VACCINIUM MACROCARPON (CRANBERRY) SEED OIL
PORTULACA PILOSA EXTRACT
TOCOPHEROL
ASCORBYL PALMITATE
SUCROSE COCOATE
GLYCINE SOJA (SOYBEAN) OIL
PALMITOYL TRIPEPTIDE-38
TIN OXIDE
TITANIUM DIOXIDE (CI 77891)
RED 28 LAKE (CI 45410)

MAY CONTAIN:

IRON OXIDES (CI 77491, 77942, 77499)
YELLOW 5 LAKE (CI 19140)
RED 7 LAKE (CI 15850)
YELLOW 6 LAKE (CI 15985)
BLUE 1 LAKE (CI 42090)